Penn State Hershey Medical Center
Hershey, Pennsylvania, 17033, United States
NCT Number: NCT02808962
The procedure is supposed to ablate the sacral lateral branches that form the medial cluneal nerves (MCN). The anatomy of the sacral lateral branches is such that, in addition to innervating the SIJ, distal branches of these nerves also innervate the skin over the buttock through MCN (12,13). SLB blocks (usually with 0.5 ml of 1% Lidocaine or 0.5% Bupivacaine) are performed proximal to the origin of both the nerves to the SIJ and the cutaneous branches. Therefore, a technically accurate block should anesthetize not only the SIJ but also the skin of the buttock regardless of the patient symptoms. Hypoesthesia of the buttock would, therefore, be a quality-assurance sign that the block has been performed in a technically correct fashion. Similarly, if the target nerves have been accurately ablated by RFA hypoesthesia of the buttock should ensue, as an expected effect of the procedure.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Hershey, Pennsylvania, 17033, United States
Typical standard of care for these patients is initial visit followed by two diagnostic blocks ((0.5 ml) of 1 % Lidocaine per level). They are asked to complete the pain diary and if they experience a 75% or more decrease in the NRS, they are scheduled for Cooled RFA of the lateral branches of S1, S2, and S3 dorsal rami nerves and of the dorsal ramus of L5 nerve.
If patients do not experience adequate pain relief after either of these injections, it is determined that the cooled RFA procedure will not work for them. Therefore, if they fail to receive adequate pain relief after either of these two injections, they will exit the study and other alternatives will be explored. The patient will also exit the study if they fail to achieve success 1 month after RFA treatment. The treatment of the study patients will not deviate from the standard of care.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A single target will be identified at the junction of the sacral ala and S1 superior articular process, corresponding to the location of the L5 dorsal ramus. Then, utilizing a stainless steel Epsilon Ruler (Kimberly Clark, Irving, TX, USA), three targets will be localized 8-10 mm lateral to the S1 and S2 posterior sacral foramen at the 2:30, 4:00, and 5:30 positions. Two targets will be localized at the S3 level. Local infiltration with 1% lidocaine and minimal sedation with IV midazolam will be utilized. Once suitable sensory and motor stimulation are verified and impedance is acceptable, each target will be anesthetized with 1 mL of 1% lidocaine prior to each lesion being created at 60 degrees centigrade for 2 minutes and 30 seconds.
Time frame: 6 months postprocedure
Time frame: 6-month postprocedure
Time frame: 6-month postprocedure
Time frame: 6-month postprocedure
Time frame: 6-month postprocedure
Binary "Yes" or "No" answer.
Milton S. Hershey Medical Center
Other
In Pursuit of the Optimal Performance of Radiofrequency Ablation of the Nerves Supplying the Posterior Sacroiliac Joint Complex.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02335190
Back Pain, Joint Diseases
London, Ontario, Canada
View Trial DetailsNCT03291470
Degenerative Osteoarthritis, Joint Diseases
Tucson, Arizona, United States
View Trial DetailsNCT06173193
Arthritis, Behavior
Jyväskylä, Finland
View Trial DetailsNCT03391323
Arthritis, Joint Disease
Spokane, Washington, United States
View Trial Details